查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566969

布鲁氏菌病疫苗市场：按类型、按疫苗、动物类型、按最终用户：2024-2033 年全球机会分析和产业预测

Brucellosis Vaccines Market By Type , By Vaccine By Animal Type By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年布鲁氏菌病疫苗市值为2亿美元，预计2024年至2033年复合年增长率为6.4%，到2033年将达4亿美元。

布鲁氏菌病疫苗是预防和控制布鲁氏菌病（一种由布氏桿菌属引起的通用感染疾病）的重要工具。该疾病感染多种牲畜，包括牛、绵羊和山羊，导致流产和生育力下降等繁殖障碍，对农业部门造成重大经济损失。在人类中，布鲁氏菌病可引起从轻微的类流感症状到严重的慢性症状的各种症状。牲畜疫苗接种是减少布氏桿菌属从动物传播给人类的关键，在公共卫生和食品安全中发挥重要作用。

全球布鲁氏菌病疫苗市场的成长是由于牲畜布鲁氏菌病发病率上升，特别是在农业活动频繁的地区，以及农民和牲畜所有者对预防布鲁氏菌病疫苗接种重要性的认识不断提高而带来的。根据世界领先的医学研究中心之一美国国立卫生研究院发表的一项研究，布氏桿菌症是最常见的通用感染疾病之一，每年影响 50 万人。随着全球对肉类和乳製品的需求不断增加，保护牲畜免受布氏桿菌症等疾病侵害的需求不断增加，进一步推动了布鲁氏菌病疫苗市场的发展。此外，由于布氏桿菌症是一种人畜共通感染疾病，可以传播给人类，因此人们专注于控制牲畜疾病以保护人类健康，这推动了对疫苗的需求。此外，不断增加的区域和国家疫苗宣传活动，特别是在布鲁氏菌病是一个重要公共卫生问题的国家，正在为市场成长做出重大贡献。此外，对「统一健康」概念的强调，即关注人类、动物和环境健康的相互联繫，正在影响布鲁氏菌病疫苗市场。这种整体方法正在导致人们综合努力控制动物和人类的布鲁氏菌病，特别是在布鲁氏菌病流行的地区。然而，开拓新的有效布鲁氏菌病疫苗的高成本阻碍了全球市场的成长。此外，由于基因突变而出现的布氏桿菌属菌疫苗抗性菌株降低了现有疫苗的有效性，并显着抑制了市场成长。相反，疫苗技术的进步，例如开发更有效、更安全的疫苗，透过提高疾病控制的有效性而促进市场成长。此外，生物技术的进步正在推动疫苗生产的创新，包括重组 DNA 技术和其他分子技术的使用。这些创新正在提高布鲁氏菌病疫苗的功效和安全性，使其更容易取得和扩展。

全球布鲁氏菌病疫苗产业分为类型、疫苗、动物类型、最终用户和地区。按类型划分，市场分为 RBS1、S19 和 B19。疫苗分为DNA疫苗、次单位疫苗、载体疫苗、重组疫苗。依动物种类可分为牛、绵羊、山羊。按最终用户划分，该细分市场分为兽医医院和诊所、动物护理中心等。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按类型划分，RBS1 细分市场在 2023 年占据主导市场占有率。

从疫苗来看，DNA疫苗领域是2023年市场的主要股东。

按动物类型划分，牛将成为 2023 年的主导部分。

按最终用户划分，兽医院/诊所在 2023 年占据了最大份额。

按地区划分，北美在 2023 年占据主导地位，而亚太地区预计在预测期内复合年增长率最高。

可以自订此报告（需要额外的费用和时间表）

  • 按产品/细分市场细分
  • 新产品开发/主要企业产品矩阵
  • 监管指引
  • 根据客户兴趣新增其他公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章布鲁氏菌病疫苗市场：依类型

  • 市场概况
  • RBS1
  • S19
  • B19

第五章布鲁氏菌病疫苗市场：依疫苗分类

  • 市场概况
  • DNA疫苗
  • 次单位疫苗
  • 载体疫苗
  • 重组疫苗

第六章布鲁氏菌病疫苗市场：依动物类型

  • 市场概况
  • 牛
  • 羊
  • 山羊

第七章布鲁氏菌病疫苗市场：依最终用户分类

  • 市场概况
  • 兽医医院和诊所
  • 动物照护中心
  • 其他的

第八章布鲁氏菌病疫苗市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国布鲁氏菌病疫苗市场
    • 加拿大布鲁氏菌病疫苗市场
    • 墨西哥布鲁氏菌病疫苗市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国布鲁氏菌病疫苗市场
    • 法国布鲁氏菌病疫苗市场
    • 英国布鲁氏菌病疫苗市场
    • 义大利布鲁氏菌病疫苗市场
    • 西班牙布鲁氏菌病疫苗市场
    • 其他欧洲布鲁氏菌病疫苗市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本布鲁氏菌病疫苗市场
    • 中国布鲁氏菌病疫苗市场
    • 澳洲布鲁氏菌病疫苗市场
    • 印度布鲁氏菌病疫苗市场
    • 韩国布鲁氏菌病疫苗市场
    • 其他亚太布鲁氏菌病疫苗市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西布鲁氏菌病疫苗市场
    • 沙乌地阿拉伯布鲁氏菌病疫苗市场
    • 南非布鲁氏菌病疫苗市场
    • 其他拉丁美洲/中东/非洲布鲁氏菌病疫苗市场

第9章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第十章 公司简介

  • Ceva Poultry
  • Colorado Serum Company
  • Creative Biolabs
  • CZ Vaccines
  • Fivet Animal Health
  • Hester Biosciences Limited
  • Indian Immunologicals Ltd
  • Jordan Bio-industries Center
  • Laboratories Tornel
  • Merck And Co., Inc.
简介目录
Product Code: A324385

The brucellosis vaccines market was valued at $0.2 billion in 2023, and is projected to reach $0.4 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.

Brucellosis vaccine is a critical tool used in the prevention and control of brucellosis, a zoonotic bacterial infection caused by Brucella species. This disease affects various livestock, including cattle, sheep, and goats, leading to reproductive failures such as abortions, reduced fertility, and significant economic losses in the agricultural sector. In humans, brucellosis can cause a range of symptoms, from mild flu-like illness to severe, chronic conditions. Vaccination of livestock is a cornerstone in reducing the transmission of Brucella from animals to humans, thus playing a vital role in public health and food safety.

The growth of the global brucellosis vaccines market is driven by rise in incidence of brucellosis in livestock, particularly in regions with significant agricultural activity, and increase in awareness among farmers and livestock owners about the importance of vaccination in preventing brucellosis. According to a study published by the National Institutes of Health-one of the world's foremost medical research centers-brucellosis is one the most common zoonotic diseases affecting 500,000 cases annually. As the global demand for meat and dairy products grows, there is a corresponding increase in the need to protect livestock from diseases like brucellosis, further driving the brucellosis vaccine market. Moreover, with brucellosis being a zoonotic disease that can be transmitted to humans, there is an increasing focus on controlling the disease in animals to protect human health, which, in turn, fosters the demand for vaccines. Furthermore, increase in trend of regional and national vaccination campaigns, particularly in countries where brucellosis is a significant public health issue, is notably contributing toward the market growth. In addition, emphasis on the One Health concept, which focuses on the interconnectedness of human, animal, and environmental health, is influencing the brucellosis vaccination market. This holistic approach is leading to integrated efforts to control brucellosis in both animals and humans, particularly in regions where the disease is endemic. However, high cost associated with development of new and effective brucellosis vaccines is hampering the growth of the global market. In addition, the emergence of vaccine-resistant strains of Brucella due to genetic variability has reduced the effectiveness of existing vaccines, which significantly restrained the market growth. On the contrary, advancements in vaccine technology, such as the development of more effective and safer vaccines, are contributing to market growth by improving the efficacy of disease control measures. Moreover, advances in biotechnology are driving innovations in vaccine production, including the use of recombinant DNA technology and other molecular techniques. These innovations are enhancing the efficacy and safety of brucellosis vaccines, making them more accessible and scalable.

The global brucellosis vaccines industry is segmented into type, vaccine, animal type, end user, and region. By type, the market is divided into RBS1, S19, and B19. As per vaccine, it is segregated into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine. By animal type, it is fragmented into cattle, sheep, and goat. Depending on end user, it is fragmented into veterinary hospitals & clinics, animal care centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the RBS1 segment dominated the market share in 2023.

As per vaccine, the DNA vaccine segment was the major shareholder in the market in 2023.

On the basis of animal type, cattle emerged as the leading segment in 2023.

Depending on end user, the veterinary hospitals & clinics segment garnered the largest share in 2023.

Region wise, North America held the dominant position in 2023; however, Asia-Pacific is expected to register highest CAGR during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global brucellosis vaccines market include Ceva Poultry, Colorado Serum Company, Creative Biolabs, CZ Vaccines, Fivet Animal Health, Hester Biosciences Limited, Indian Immunologicals Ltd, Jordan Bio-industries Center, Laboratories Tornel, and Merck & Co., Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Market share analysis of players by products/segments
  • New Product Development/ Product Matrix of Key Players
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • RBS1
  • S19
  • B19

By Vaccine

  • DNA Vaccine
  • Subunit Vaccine
  • Vector Vaccine
  • Recombinant Vaccine

By Animal Type

  • Cattle
  • Sheep
  • Goat

By End User

  • Veterinary Hospitals and Clinics
  • Animal Care Centers
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Ceva Poultry
    • Colorado Serum Company
    • Creative Biolabs
    • CZ Vaccines
    • Fivet Animal Health
    • Hester Biosciences Limited
    • Indian Immunologicals Ltd
    • Jordan Bio-industries Center
    • Laboratories Tornel
    • Merck & Co., Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: BRUCELLOSIS VACCINES MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. RBS1
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. S19
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. B19
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: BRUCELLOSIS VACCINES MARKET, BY VACCINE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Vaccine
  • 5.2. DNA Vaccine
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Subunit Vaccine
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Vector Vaccine
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Recombinant Vaccine
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: BRUCELLOSIS VACCINES MARKET, BY ANIMAL TYPE

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Animal Type
  • 6.2. Cattle
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Sheep
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Goat
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: BRUCELLOSIS VACCINES MARKET, BY END USER

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By End User
  • 7.2. Veterinary Hospitals And Clinics
    • 7.2.1. Key Market Trends, Growth Factors and Opportunities
    • 7.2.2. Market Size and Forecast, By Region
    • 7.2.3. Market Share Analysis, By Country
  • 7.3. Animal Care Centers
    • 7.3.1. Key Market Trends, Growth Factors and Opportunities
    • 7.3.2. Market Size and Forecast, By Region
    • 7.3.3. Market Share Analysis, By Country
  • 7.4. Other
    • 7.4.1. Key Market Trends, Growth Factors and Opportunities
    • 7.4.2. Market Size and Forecast, By Region
    • 7.4.3. Market Share Analysis, By Country

CHAPTER 8: BRUCELLOSIS VACCINES MARKET, BY REGION

  • 8.1. Market Overview
    • 8.1.1 Market Size and Forecast, By Region
  • 8.2. North America
    • 8.2.1. Key Market Trends and Opportunities
    • 8.2.2. Market Size and Forecast, By Type
    • 8.2.3. Market Size and Forecast, By Vaccine
    • 8.2.4. Market Size and Forecast, By Animal Type
    • 8.2.5. Market Size and Forecast, By End User
    • 8.2.6. Market Size and Forecast, By Country
    • 8.2.7. U.S. Brucellosis Vaccines Market
      • 8.2.7.1. Market Size and Forecast, By Type
      • 8.2.7.2. Market Size and Forecast, By Vaccine
      • 8.2.7.3. Market Size and Forecast, By Animal Type
      • 8.2.7.4. Market Size and Forecast, By End User
    • 8.2.8. Canada Brucellosis Vaccines Market
      • 8.2.8.1. Market Size and Forecast, By Type
      • 8.2.8.2. Market Size and Forecast, By Vaccine
      • 8.2.8.3. Market Size and Forecast, By Animal Type
      • 8.2.8.4. Market Size and Forecast, By End User
    • 8.2.9. Mexico Brucellosis Vaccines Market
      • 8.2.9.1. Market Size and Forecast, By Type
      • 8.2.9.2. Market Size and Forecast, By Vaccine
      • 8.2.9.3. Market Size and Forecast, By Animal Type
      • 8.2.9.4. Market Size and Forecast, By End User
  • 8.3. Europe
    • 8.3.1. Key Market Trends and Opportunities
    • 8.3.2. Market Size and Forecast, By Type
    • 8.3.3. Market Size and Forecast, By Vaccine
    • 8.3.4. Market Size and Forecast, By Animal Type
    • 8.3.5. Market Size and Forecast, By End User
    • 8.3.6. Market Size and Forecast, By Country
    • 8.3.7. Germany Brucellosis Vaccines Market
      • 8.3.7.1. Market Size and Forecast, By Type
      • 8.3.7.2. Market Size and Forecast, By Vaccine
      • 8.3.7.3. Market Size and Forecast, By Animal Type
      • 8.3.7.4. Market Size and Forecast, By End User
    • 8.3.8. France Brucellosis Vaccines Market
      • 8.3.8.1. Market Size and Forecast, By Type
      • 8.3.8.2. Market Size and Forecast, By Vaccine
      • 8.3.8.3. Market Size and Forecast, By Animal Type
      • 8.3.8.4. Market Size and Forecast, By End User
    • 8.3.9. UK Brucellosis Vaccines Market
      • 8.3.9.1. Market Size and Forecast, By Type
      • 8.3.9.2. Market Size and Forecast, By Vaccine
      • 8.3.9.3. Market Size and Forecast, By Animal Type
      • 8.3.9.4. Market Size and Forecast, By End User
    • 8.3.10. Italy Brucellosis Vaccines Market
      • 8.3.10.1. Market Size and Forecast, By Type
      • 8.3.10.2. Market Size and Forecast, By Vaccine
      • 8.3.10.3. Market Size and Forecast, By Animal Type
      • 8.3.10.4. Market Size and Forecast, By End User
    • 8.3.11. Spain Brucellosis Vaccines Market
      • 8.3.11.1. Market Size and Forecast, By Type
      • 8.3.11.2. Market Size and Forecast, By Vaccine
      • 8.3.11.3. Market Size and Forecast, By Animal Type
      • 8.3.11.4. Market Size and Forecast, By End User
    • 8.3.12. Rest of Europe Brucellosis Vaccines Market
      • 8.3.12.1. Market Size and Forecast, By Type
      • 8.3.12.2. Market Size and Forecast, By Vaccine
      • 8.3.12.3. Market Size and Forecast, By Animal Type
      • 8.3.12.4. Market Size and Forecast, By End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key Market Trends and Opportunities
    • 8.4.2. Market Size and Forecast, By Type
    • 8.4.3. Market Size and Forecast, By Vaccine
    • 8.4.4. Market Size and Forecast, By Animal Type
    • 8.4.5. Market Size and Forecast, By End User
    • 8.4.6. Market Size and Forecast, By Country
    • 8.4.7. Japan Brucellosis Vaccines Market
      • 8.4.7.1. Market Size and Forecast, By Type
      • 8.4.7.2. Market Size and Forecast, By Vaccine
      • 8.4.7.3. Market Size and Forecast, By Animal Type
      • 8.4.7.4. Market Size and Forecast, By End User
    • 8.4.8. China Brucellosis Vaccines Market
      • 8.4.8.1. Market Size and Forecast, By Type
      • 8.4.8.2. Market Size and Forecast, By Vaccine
      • 8.4.8.3. Market Size and Forecast, By Animal Type
      • 8.4.8.4. Market Size and Forecast, By End User
    • 8.4.9. Australia Brucellosis Vaccines Market
      • 8.4.9.1. Market Size and Forecast, By Type
      • 8.4.9.2. Market Size and Forecast, By Vaccine
      • 8.4.9.3. Market Size and Forecast, By Animal Type
      • 8.4.9.4. Market Size and Forecast, By End User
    • 8.4.10. India Brucellosis Vaccines Market
      • 8.4.10.1. Market Size and Forecast, By Type
      • 8.4.10.2. Market Size and Forecast, By Vaccine
      • 8.4.10.3. Market Size and Forecast, By Animal Type
      • 8.4.10.4. Market Size and Forecast, By End User
    • 8.4.11. South Korea Brucellosis Vaccines Market
      • 8.4.11.1. Market Size and Forecast, By Type
      • 8.4.11.2. Market Size and Forecast, By Vaccine
      • 8.4.11.3. Market Size and Forecast, By Animal Type
      • 8.4.11.4. Market Size and Forecast, By End User
    • 8.4.12. Rest of Asia-Pacific Brucellosis Vaccines Market
      • 8.4.12.1. Market Size and Forecast, By Type
      • 8.4.12.2. Market Size and Forecast, By Vaccine
      • 8.4.12.3. Market Size and Forecast, By Animal Type
      • 8.4.12.4. Market Size and Forecast, By End User
  • 8.5. LAMEA
    • 8.5.1. Key Market Trends and Opportunities
    • 8.5.2. Market Size and Forecast, By Type
    • 8.5.3. Market Size and Forecast, By Vaccine
    • 8.5.4. Market Size and Forecast, By Animal Type
    • 8.5.5. Market Size and Forecast, By End User
    • 8.5.6. Market Size and Forecast, By Country
    • 8.5.7. Brazil Brucellosis Vaccines Market
      • 8.5.7.1. Market Size and Forecast, By Type
      • 8.5.7.2. Market Size and Forecast, By Vaccine
      • 8.5.7.3. Market Size and Forecast, By Animal Type
      • 8.5.7.4. Market Size and Forecast, By End User
    • 8.5.8. Saudi Arabia Brucellosis Vaccines Market
      • 8.5.8.1. Market Size and Forecast, By Type
      • 8.5.8.2. Market Size and Forecast, By Vaccine
      • 8.5.8.3. Market Size and Forecast, By Animal Type
      • 8.5.8.4. Market Size and Forecast, By End User
    • 8.5.9. South Africa Brucellosis Vaccines Market
      • 8.5.9.1. Market Size and Forecast, By Type
      • 8.5.9.2. Market Size and Forecast, By Vaccine
      • 8.5.9.3. Market Size and Forecast, By Animal Type
      • 8.5.9.4. Market Size and Forecast, By End User
    • 8.5.10. Rest of LAMEA Brucellosis Vaccines Market
      • 8.5.10.1. Market Size and Forecast, By Type
      • 8.5.10.2. Market Size and Forecast, By Vaccine
      • 8.5.10.3. Market Size and Forecast, By Animal Type
      • 8.5.10.4. Market Size and Forecast, By End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top Winning Strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top Player Positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Ceva Poultry
    • 10.1.1. Company Overview
    • 10.1.2. Key Executives
    • 10.1.3. Company Snapshot
    • 10.1.4. Operating Business Segments
    • 10.1.5. Product Portfolio
    • 10.1.6. Business Performance
    • 10.1.7. Key Strategic Moves and Developments
  • 10.2. Colorado Serum Company
    • 10.2.1. Company Overview
    • 10.2.2. Key Executives
    • 10.2.3. Company Snapshot
    • 10.2.4. Operating Business Segments
    • 10.2.5. Product Portfolio
    • 10.2.6. Business Performance
    • 10.2.7. Key Strategic Moves and Developments
  • 10.3. Creative Biolabs
    • 10.3.1. Company Overview
    • 10.3.2. Key Executives
    • 10.3.3. Company Snapshot
    • 10.3.4. Operating Business Segments
    • 10.3.5. Product Portfolio
    • 10.3.6. Business Performance
    • 10.3.7. Key Strategic Moves and Developments
  • 10.4. CZ Vaccines
    • 10.4.1. Company Overview
    • 10.4.2. Key Executives
    • 10.4.3. Company Snapshot
    • 10.4.4. Operating Business Segments
    • 10.4.5. Product Portfolio
    • 10.4.6. Business Performance
    • 10.4.7. Key Strategic Moves and Developments
  • 10.5. Fivet Animal Health
    • 10.5.1. Company Overview
    • 10.5.2. Key Executives
    • 10.5.3. Company Snapshot
    • 10.5.4. Operating Business Segments
    • 10.5.5. Product Portfolio
    • 10.5.6. Business Performance
    • 10.5.7. Key Strategic Moves and Developments
  • 10.6. Hester Biosciences Limited
    • 10.6.1. Company Overview
    • 10.6.2. Key Executives
    • 10.6.3. Company Snapshot
    • 10.6.4. Operating Business Segments
    • 10.6.5. Product Portfolio
    • 10.6.6. Business Performance
    • 10.6.7. Key Strategic Moves and Developments
  • 10.7. Indian Immunologicals Ltd
    • 10.7.1. Company Overview
    • 10.7.2. Key Executives
    • 10.7.3. Company Snapshot
    • 10.7.4. Operating Business Segments
    • 10.7.5. Product Portfolio
    • 10.7.6. Business Performance
    • 10.7.7. Key Strategic Moves and Developments
  • 10.8. Jordan Bio-industries Center
    • 10.8.1. Company Overview
    • 10.8.2. Key Executives
    • 10.8.3. Company Snapshot
    • 10.8.4. Operating Business Segments
    • 10.8.5. Product Portfolio
    • 10.8.6. Business Performance
    • 10.8.7. Key Strategic Moves and Developments
  • 10.9. Laboratories Tornel
    • 10.9.1. Company Overview
    • 10.9.2. Key Executives
    • 10.9.3. Company Snapshot
    • 10.9.4. Operating Business Segments
    • 10.9.5. Product Portfolio
    • 10.9.6. Business Performance
    • 10.9.7. Key Strategic Moves and Developments
  • 10.10. Merck And Co., Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Key Executives
    • 10.10.3. Company Snapshot
    • 10.10.4. Operating Business Segments
    • 10.10.5. Product Portfolio
    • 10.10.6. Business Performance
    • 10.10.7. Key Strategic Moves and Developments